Skip to NavigationSkip to content

News

A further 38 hospital have been invited to apply for foundation trust status after winning three stars in the recent NHS performance ratings.
Aventis may struggle to replace revenue from its ageing blockbusters despite a strong performance in the second quarter, according to analysts.
Strong sales of established and new products in the second quarter saw both Bristol-Myers Squibb and Eli Lilly beat analysts' earning forecasts.
Growth in new products are helping to plug the sizeable gap left by three of AstraZeneca's ageing blockbusters Prilosec (Losec), Zestril and Nolvadex.
The weakness of the US dollar more than halved Sanofi-Synthelabo's earnings in the first half of this year, but disguised strong underlying growth...
ACE inhibitors have been recommended as first line treatment for chronic heart failure as part of a comprehensive set of NICE guidelines for...
A new training agency specialising in preparing pharmaceutical spokespeople to deal with modern media techniques has been launched.
The pharmaceutical industry could be granted access to data from the UK's Yellow Card adverse effect warning system to assist the development of...
Pfizer's blockbuster arthritis drug Celebrex is set to gain a European orphan drug licence for the treatment of a rare pre-cancerous condition, after...
Generic competition and wholesaler de-stocking are among the problems besetting two of the industry's biggest hitters, GlaxoSmithKline and...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches